III期非小细胞肺癌的管理:ASCO指南
ASCO专家小组基于1990至2021年发表的系统综述、Meta分析和随机对照试验制定III期非小细胞肺癌管理指南,文献检索纳入127项相关研究,围绕疑似III期患者的评估与分期检查、手术管理、新辅助与辅助治疗及不可切除患者的治疗形成循证推荐。
要点
- 指南针对疑似III期非小细胞肺癌的评估与分期检查给出循证推荐。
- 指南涵盖可手术患者的手术管理及新辅助、辅助治疗策略。
- 指南涵盖不可切除III期非小细胞肺癌患者的治疗推荐。
核心结论
- 专家小组针对III期非小细胞肺癌的评估与分期、手术管理、新辅助与辅助治疗及不可切除患者的治疗制定了循证推荐。
研究设计与样本
- 由肿瘤内科、胸外科、放射肿瘤科、肺部肿瘤科、社区肿瘤科、研究方法学及患者倡导专家组成专家小组,检索1990年至2021年发表的系统综述、Meta分析和随机对照试验。
- 关注的结局包括生存、无病生存或无复发生存及生活质量,专家组成员结合现有证据与非正式共识制定循证指南推荐。
主要发现
- 文献检索共识别127项相关研究作为该指南的证据基础。
关键数值与推荐
- 推荐内容涵盖疑似III期非小细胞肺癌患者的评估与分期检查、手术管理、新辅助与辅助治疗及不可切除III期患者的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). METHODS: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 127 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
引用
- Daly ME, Singh N, Ismaila N, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2021. PMID: 34936470. doi:10.1200/JCO.21.02528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。